Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo

Cancer Research

Volumn 58, Issue 22, 1998, Pages 5206-5215

  Crawford, Howard C ^a   Matrisian, Lynn M ^a   Liaw, Lucy ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Maine Medical Center Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL SURVIVAL; DISEASE COURSE; GENE EXPRESSION; HOST RESISTANCE; METASTASIS; MOUSE; NONHUMAN; NULL CELL; PRIORITY JOURNAL; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOGENS; CARCINOMA; CARCINOMA, SQUAMOUS CELL; CELL COUNT; CELL DIVISION; DISEASE PROGRESSION; FEMALE; MALE; METHYLNITRONITROSOGUANIDINE; MICE; NEOPLASM PROTEINS; OSTEOPONTIN; PAPILLOMA; PHENOTYPE; SIALOGLYCOPROTEINS; SKIN NEOPLASMS;

EID: 0032533862     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Denhardt, D. T., Lopez, C. A., Rollo, E. E., Hwang, S. M., An, X. R., and Walther, S. E. Osteopontin-induced modifications of cellular functions. Ann. NY Acad. Sci., 760: 127-142, 1995.
2. Craig, A. M., Bowden, G. T., Chambers, A. F., Spearman, M. A., Greenberg, A. H., Wright, J. A., McLeod, M., and Denhardt, D. T. Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int. J. Cancer, 46: 133-137, 1990.
3. Senger, D. R., Perruzzi, C. A., and Papadopoulos, A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res., 9: 1291-1299, 1989.
4. Brown, L. F., Papadopoulos-Sergiou, A., Berse, B., Manseau, E. J., Tognazzi, K., Perruzzi, C. A., Dvorak, H. F., and Senger, D. R. Osteopontin expression and distribution in human carcinomas. Am. J. Pathol., 145: 610-623, 1994.
5. Craig, A. M., Smith, J. H., and Denhardt, D. T. Osteopontin, a transformation-associated cell adhesion phosphoprotein, is induced by 12-O-tetradecanoylphorbol 13-acetate in mouse epidermis. J. Biol. Chem., 264: 9682-9689, 1989.
6. Hashimoto, Y., Tajima, O., Hashiba, H., Nose, K., and Kuroki, T. Elevated expression of secondary, but not early, responding genes to phorbol ester tumor promoters in papillomas and carcinomas of mouse skin. Mol. Carcinog., 3: 302-308, 1990.
7. Su, L., Mukherjee, A. B., and Mukherjee, B. B. Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells. Oncogene, 10: 2163-2169, 1995.
8. Gardner, H. A., Berse, B., and Senger, D. R. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene, 9: 2321-2326, 1994.
9. Behrend, E. I., Craig, A. M., Wilson, S. M., Denhardt, D. T., and Chambers, A. F. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res., 54: 832-837, 1994.
10. Oates, A. J., Barraclough, R., and Rudland, P. S. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene, 13: 97-104, 1996.
11. Hu, D. D., Hoyer, J. R., and Smith, J. W. Characterization of the interaction between integrins and recombinant human osteopontin. Ann. NY Acad. Sci., 760: 312-314, 1995.
12. Smith, L. L., Cheung, H. K., Ling, L. E., Chen, J., Sheppard, D., Pytela, R., and Giachelli, C. M. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by α9β1 integrin. J. Biol. Chem., 271: 28485-28491, 1996.
13. Weber, G. F., Ashkar, S., Glimcher, M. J., and Cantor, H. Receptor-ligand interaction between CD44 and osteopontin Eta-1. Science (Washington DC), 271: 509-512, 1996.
14. Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., and Cheresh, D. A. Definition of two angiogenic pathways by distinct alpha v integrins. Science (Washington DC), 270: 1500-1502, 1995.
15. Naot, D., Sionov, R. V., and Ish-Shalom, D. CD44: structure, function, and association with the malignant process. Adv. Cancer Res., 71: 241-319, 1997.
16. Liaw, L., Birk, D. E., Ballas, C. B., Whittsit, J. M., Davidson, J. M., and Hogan, B. L. M. Altered wound healing in mice lacking a functional osteopontin gene (sppl). J. Clin. Invest., 101: 1468-1478, 1998.
17. Giachelli, C., Bae, N., Lombardi, D., Majesky, M., and Schwartz, S. M. Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR). Biochem. Biophys. Res. Commun., 177: 867-873, 1991.
18. Liaw, L., Almeida, M., Hart, C. E., Schwartz, S. M., and Giachelli, C. M. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ. Res., 74: 214-224, 1994.
19. Shepherd, V. L., Abdolrasulnia, R., Garrett, M., and Cowan, H. B. Down-regulation of mannose receptor activity in macrophages after treatment with lipopolysaccharide and phorbol esters. J. Immunol., 145: 1530-1536, 1990.
20. Ford, V. A., Stringer, C., and Kennel, S. J. Thrombomodulin is preferentially expressed in Balb/c lung microvessels. J. Biol. Chem., 267: 5446-5450, 1992.
21. Burns, P. A., Kemp, C. J., Gannon, J. V., Lane, D. P., Bremner, R., and Balmain, A. Loss of heterozygosity and mutational alterations of the p53 gene in skin tumours of interspecific hybrid mice. Oncogene, 6: 2363-2369, 1991.
22. Stoler, A. B., Stenback, F., and Balmain, A. The conversion of mouse skin squamous cell carcinomas to spindle cell carcinomas is a recessive event. J. Cell Biol., 122: 1103-1117, 1993.
23. Denhardt, D. T., and Chambers, A. F. Overcoming obstacles to metastasis-defenses against host defenses: osteopontin OPN as a shield against attack by cytotoxic host cells. J. Cell Biochem., 56: 48-51, 1994.
24. Giachelli, C. M., Lombardi, D., Johnson, R. J., Murry, C. E., and Almeida, M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am. J. Pathol., 152: 353-358, 1998.
25. Weber, G. F., and Cantor, H. The immunology of Eta-1/osteopontin. Cytokine Growth Factor Rev., 7: 241-248, 1996.
26. Nasu, K., Ishida, T., Setoguchi, M., Higuchi, Y., Akizuki, S., and Yamamoto, S. Expression of wild-type and mutated rabbit osteopontin in Escherichia coli and their effects on adhesion and migration of P388D1 cells. Biochem. J., 307: 257-265, 1995.
27. Stahl, P. D. The mannose receptor and other macrophage lectins. Curr. Opin. Immunol., 4: 49-52, 1992.
28. Mokoena, T., and Gordon, S. Human macrophage activation. Modulation of mannosyl, fucosyl receptor activity in vitro by lymphokines, gamma and alpha interferons, and dexamethasone. J. Clin. Invest., 75: 624-631, 1985.
29. Chroneos, Z., and Shepherd, V. L. Differential regulation of the mannose and SP-A receptors on macrophages. Am. J. Physiol., 269: L721-L726, 1995.
30. Senger, D. R., and Perruzzi, C. A. Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells. Cancer Res., 45: 5818-5823, 1985.
31. Craig, A. M., Nemir, M., Mukherjee, B. B., Chambers, A. F., and Denhardt, D. T. Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: enhanced expression in H-ras-transformed 3T3 cells. Biochem. Biophys. Res. Commun., 157: 166-173, 1988.
32. Singhal, H., Bautista, D. S., Tonkin, K. S., O'Malley, F. P., Tuck, A. B., Chambers, A. F., and Harris, J. F. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin. Cancer Res., 3: 605-611, 1997.
33. Tuck, A. B., O'Malley, F. P., Singhal, H., Tonkin, K. S., Harris, J. F., Bautista, D., and Chambers, A. F. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch. Pathol. Lab. Med., 121: 578-584, 1997.
34. Chambers, A. F., Wilson, S. M., Kerkvliet, N., O'Malley, F. P., Harris, J. F., and Casson, A. G. Osteopontin expression in lung cancer. Lung Cancer, 15: 311-323, 1996.
35. Singh, R. P., Patarca, R., Schwartz, J., Singh, P., and Cantor, H. Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo. J. Exp. Med., 171: 1931-1942, 1990.
36. Feng, B., Rollo, E. E., and Denhardt, D. T. Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by a targeted ribozyme. Clin. Exp. Metastasis, 13: 453-462, 1995.
37. Rollo, E. E., Laskin, D. L., and Denhardt, D. T. Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. J. Leukoc. Biol., 60: 397-404, 1996.
38. Koop, S., Schmidt, E. E., MacDonald, I. C., Morris, V. L., Khokha, R., Grattan, M., Leone, J., Chambers, A. F., and Groom, A. C. Independence of metastatic ability and extravasation: metastatic ras-transformed and control fibroblasts extravasate equally well. Proc. Natl. Acad. Sci. USA, 93: 11080-11084, 1996.
39. Scatena, M., Almeida, M., Chaisson, M. L., Fausto, N., Nicosia, R. F., and Giachelli C. M. NF-κB mediates αv/β3 integrin-induced endothelial cell survival. J. Cell Biol., 141: 1083-1093, 1998.
40. Tezuka, K., Denhardt, D. T., Rodan, G. A., and Harada, S. Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor. J. Biol. Chem., 271: 22713-22717, 1996.
41. Chambers, A. F. Regulation of function of osteopontin in ras-transformed cells. Ann. NY Acad. Sci., 760: 101-108, 1995.
42. Grigoriadis, A. E., Schellander, K., Wang, Z. Q., and Wagner, E. F. Osteoblasts are target cells for transformation in c-fos transgenic mice. J. Cell Biol., 122: 685-701, 1993.
43. Castagnola, P., Bet, P., Quarto, R., Gennari, M., and Cancedda, R. cDNA cloning and gene expression of chicken osteopontin. Expression of osteopontin mRNA in chondrocytes is enhanced by trypsin treatment of cells. J. Biol. Chem., 266: 9944-9949, 1991.
44. Barraclough, R., Chen, H. J., Davies, B. R., Davies, M. P., Ke, Y., Lloyd, B. H., Oates, A., and Rudland, P. S. Use of DNA transfer in the induction of metastasis in experimental mammary systems. Biochem. Soc. Symp., 63: 273-294, 1998.
45. Liaw, L., Lindner, V., Schwartz, S. M., Chambers, A. F., and Giachelli, C. M. Osteopontin and β3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate arg-gly-asp-dependent endothelial migration in vitro. Circ. Res., 77: 665-672, 1995.
46. Srivatsa, S. S., Fitzpatrick, L. A., Tsao, P. W., Reilly, T. M., Holmes, D. R., Jr., Schwartz, R. S., and Mousa, S. A. Selective αvβ3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin αvβ3 and osteopontin expression during neointima formation. Cardiovasc. Res., 36: 408-428, 1997.
47. Brooks, P. C., Stromblad, S., Sanders, I. C., von Schalscha, T. L., Aimes, R. T., Stetler-Stevenson, W. G., Quigley, J. P., and Cheresh, D. A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell, 85: 683-693, 1996.
48. Neame, P. J., and Butler, W. T. Posttranslational modification in rat bone osteopontin. Connect. Tissue Res., 35: 145-150, 1996.
49. Sorensen, E. S., Hojrup, P., and Petersen, T. E. Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci., 4: 2040-2049, 1995.
50. Beninati, S., Senger, D. R., Corella-Miele, E., Mukherjee, A. B., Chackalaparampil, I., Shanmugam, V., Singh, K., and Mukherjee, B. B. Osteopontin: its transglutaminase-catalyzed posttranslational modifications and cross-linking to fibronectin. J. Biochem., 115: 675-682, 1994.
51. Shanmugam, V., Chackalaparampil, I., Kundu, G. C., Mukherjee, A. B., and Mukherjee, B. B. Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells. Biochemistry, 36: 5729-5738, 1997.
52. Senger, D. R., and Perruzzi, C. A. Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim. Biophys. Acta, 1314: 13-24, 1996.
53. Singh, K., DeVouge, M. W., and Mukherjee, B. B. Physiological properties and differential glycosylation of phosphorylated and nonphosphorylated forms of osteopontin secreted by normal rat kidney cells. J. Biol. Chem., 265: 18696-18701, 1990.
54. Senger, D. R., Perruzzi, C. A., Papadopoulos-Sergiou, A., and Van de Water, L. Adhesive properties of osteopontin: regulation by a naturally occurring thrombincleavage in close proximity to the GRGDS cell-binding domain. Mol. Biol. Cell, 5: 565-574, 1994.
55. Liaw, L., Skinner, M. P., Raines, E. W., Ross, R., Cheresh, D. A., Schwartz, S. M., and Giachelli, C. M. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of αvβ3 in smooth muscle cell migration to osteopontin in vitro. J. Clin. Invest., 95: 713-724, 1995.
56. Gillespie, M. T., Thomas, R. J., Pu, Z. Y., Zhou, H., Martin, T. J., and Findlay, D. M. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int. J. Cancer, 73: 812-815, 1997.
57. Bellahcene, A., and Castronovo, V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am. J. Pathol., 146: 95-100, 1995.
58. Hirota, S., Ito, A., Nagoshi, J., Takeda, M., Kurata, A., Takatsuka, Y., Kohri, K., Nomura, S., and Kitamura, Y. Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. Lab. Invest., 72: 64-69, 1995.
59. Casson, A. G., Wilson, S. M., McCart, J. A., O'Malley, F. P., Ozcelik, H., Tsao, M. S., and Chambers, A. F. Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int. J. Cancer, 72: 739-745, 1997.